TY - JOUR
T1 - Highlights from the plenary session
T2 - cellular and molecular mechanisms of disease (I)
AU - Zimmermann, Jonas
AU - Schreiber, Adrian
AU - Heeringa, Peter
AU - Te Velde-Keyzer, Charlotte A
N1 - © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
PY - 2025/3
Y1 - 2025/3
N2 - In this plenary session of the Vasculitis Workshop 2024, pioneering translational research on autoimmune vasculitis, particularly ANCA-associated vasculitis (AAV), was presented, highlighting advancements in our understanding of disease mechanisms and promising therapeutic prospects. Advances in elucidating molecular pathways, such as IL-17 and IFN-I, pave the way for specific treatments. Preclinical studies have revealed the gut microbiome's role in the pathogenesis of MPO-AAV and demonstrate the therapeutic potential of dietary interventions. Furthermore, research into the protective role of Tregs has shed light on potential new targets for therapeutic interventions. Innovative approaches, such as CAR-T cell therapy and Deoxy Mab DX-1/DX-3, show significant promise in mitigating AAV pathology. These advancements underscore the transformative potential of translational research. By enhancing our understanding of disease mechanisms, these findings pave the way for the development of personalized and effective therapies, ultimately enhancing patient outcomes.
AB - In this plenary session of the Vasculitis Workshop 2024, pioneering translational research on autoimmune vasculitis, particularly ANCA-associated vasculitis (AAV), was presented, highlighting advancements in our understanding of disease mechanisms and promising therapeutic prospects. Advances in elucidating molecular pathways, such as IL-17 and IFN-I, pave the way for specific treatments. Preclinical studies have revealed the gut microbiome's role in the pathogenesis of MPO-AAV and demonstrate the therapeutic potential of dietary interventions. Furthermore, research into the protective role of Tregs has shed light on potential new targets for therapeutic interventions. Innovative approaches, such as CAR-T cell therapy and Deoxy Mab DX-1/DX-3, show significant promise in mitigating AAV pathology. These advancements underscore the transformative potential of translational research. By enhancing our understanding of disease mechanisms, these findings pave the way for the development of personalized and effective therapies, ultimately enhancing patient outcomes.
KW - Humans
KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology
KW - Gastrointestinal Microbiome/physiology
KW - Translational Research, Biomedical
KW - T-Lymphocytes, Regulatory/immunology
KW - Interleukin-17
U2 - 10.1093/rheumatology/keae411
DO - 10.1093/rheumatology/keae411
M3 - Review article
C2 - 40071418
SN - 1462-0324
VL - 64
SP - i85-i87
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - Supplement_1
ER -